Phenylpiracetam — Research Profile

Phenylpiracetam rapidly downregulates the dopamine and norepinephrine receptors it activates, leading to diminished effects within 3-5 days of consecutive use. This is typical of dopaminergic compounds. The best approach is to use it on an as-needed basis (2-3 times per week maximum) rather than daily, reserving it for demanding cognitive or physical challenges.

Phenylpiracetam is in a regulatory gray area in many countries. It is a prescription drug in Russia (as Phenotropil), an unscheduled compound in the US (not FDA-approved but not controlled), and banned by WADA for competitive athletes. It is not approved as a dietary supplement by the FDA. Availability varies by country — check local regulations.

Both enhance wakefulness and cognition, but through different mechanisms. Modafinil primarily affects histamine and orexin systems for wakefulness with mild dopamine reuptake inhibition. Phenylpiracetam has broader effects on glutamate, dopamine, and norepinephrine systems. Phenylpiracetam is more stimulating and builds tolerance faster. Modafinil has more clinical data, a clearer legal status, and less rapid tolerance development. Both require caution and ideally medical guidance.

Commercial phenylpiracetam is typically sold as the racemic powder or capsules, a 50/50 mix of R- and S-enantiomers. Research indicates the R-enantiomer is the more active atypical dopamine reuptake inhibitor, but single-enantiomer products are not standardized on the consumer market and no head-to-head bioavailability trials in people have compared available forms. There is no evidence supporting one commercial form over another.

The human evidence is thin and comes mostly from small, older Russian studies in neurological patients rather than healthy adults. In one study of 99 patients with encephalopathy from stroke, trauma, or brain-tumor surgery, 200 mg/day for a month improved motor coordination, memory, and attention. A pharmacology review describes it as more potent than piracetam and used for a wider range of indications, but rigorous placebo-controlled trials of cognitive enhancement in healthy people are lacking, so broad 'brain-boosting' claims are not proven.

No standardized over-the-counter dose is established. The one published clinical study grounded here used 200 mg/day for one month in patients with encephalopathy, and the drug is marketed in 100 mg tablets, but no validated daily range for self-supplementation exists. Because it is a prescription drug in Russia and an unapproved substance elsewhere, this figure reflects supervised clinical dosing rather than a self-supplementation regimen, and dosing for cognitive enhancement in healthy adults has not been formally determined.

No study has directly compared timing. Because phenylpiracetam is a stimulant with a 3-5 hour half-life and can cause insomnia and psychomotor agitation, taking it in the morning or early day is the practical way to limit sleep disruption. This is a reasoning from its pharmacology rather than a tested schedule.

Reported effects include insomnia and sleep disturbance, psychomotor agitation, flushing and a sensation of warmth, and increased blood pressure, consistent with its stimulant action. Extended use may produce an appetite-suppressing (anorexic) effect. The overall side-effect data are limited to small clinical studies and case observations, so the full frequency and severity profile is not well characterized.

No formal human drug-interaction studies have been published, so specific interactions are not documented. Its stimulant and dopamine-reuptake-inhibiting pharmacology creates a theoretical concern with other stimulants, sympathomimetics, and blood-pressure medications, since additive effects on heart rate and blood pressure are plausible. Anyone on prescription medication should treat these as unquantified risks rather than assume the combination is safe.

There is no evidence-based case for routine supplementation. Phenylpiracetam is a prescription medicine in Russia used under medical supervision for neurological conditions, and elsewhere it is an unapproved drug that is unlawful to sell as a supplement, with only small patient studies behind it. Competitive athletes in particular must avoid it because WADA prohibits it in competition, and no healthy population has trial evidence supporting self-directed use.

Phenylpiracetam is absorbed quickly, with peak blood levels reached within about an hour and an elimination half-life of roughly 3-5 hours, so its acute stimulant-like effects on alertness are felt the same day. The therapeutic cognitive and motor improvements reported in Russian patient studies were measured after sustained daily dosing: the encephalopathy trial gave 200 mg/day over one month before assessing benefit. No trial has defined an onset window for cognitive enhancement in healthy people.

Long-term safety is not established. The longest human data come from small Russian clinical studies of roughly one month, such as the encephalopathy trial that dosed 200 mg/day for a month, and no controlled trial has tracked healthy users beyond that. It is an unapproved drug in the US whose use in dietary supplements is unlawful, and a prescription-only medicine in Russia, so there is no basis for treating it as a safe daily supplement.

Yes. No safe upper limit has been defined, and because phenylpiracetam acts as a stimulant and dopamine reuptake inhibitor, excess doses can cause insomnia, psychomotor agitation, flushing, and elevated blood pressure. Published human toxicology is minimal, so the dose at which harm occurs is not characterized. It is also banned in athletic competition by WADA, so overuse carries a doping-sanction risk for competitors.

No formal studies have tested phenylpiracetam alongside other supplements, so combinations are unproven and not risk-assessed. Because it works as a stimulant and dopamine reuptake inhibitor, stacking it with caffeine or other stimulants can plausibly compound over-stimulation, insomnia, and blood-pressure elevation. Given the absence of interaction data and its unapproved status, there is no evidence base to recommend any particular pairing.

Phenylpiracetam is not a legal dietary supplement in the US; the FDA treats it as an unapproved drug whose use in supplements or food is unlawful, and in Russia it is a prescription medicine. Products sold online are gray-market research chemicals that carry no FDA-verified identity, purity, or dose standardization, so contents cannot be assumed to match the label. There is no recognized quality standard to shop against for this compound.